/SVA
Sinovac Biotech Ltd.
SVA • NASDAQSVA • NASDAQ • Healthcare
$6.47+0.00%+0.00
$6.47+0.00%(+0.00)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
70Bullish
Risk
80Low Risk
Momentum
50Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
59.5%▲5.4pp
Revenue after COGS
Operating
-122.0%▼90.7pp
After operating expenses
Net
-22.3%▼29.9pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-6.4
Price vs earnings
EV/EBITDA
54.2
Enterprise value
FCF Yield
-6.5%
Cash generation
Earnings Yield
-15.5%
Inverse of P/E
Capital Efficiency
-3
GoAI Quality ScorePoor
ROEReturn on Equity
-1.1%Weak
ROAReturn on Assets
-0.7%Weak
ROICReturn on Invested Capital
-4.3%Weak
Financial Health
Current RatioHealthy
10.31
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
161.08x
Debt repayment capacity (<3x)
Income QualityWeak
-0.40
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $448.27M | $1.49B | $19.37B | $510.62M | $246.05M |
| Gross Profit | $266.75M | $808.30M | $18.30B | $443.44M | $213.58M |
| Gross Margin | 59.5% | 54.1% | 94.5% | 86.8% | 86.8% |
| Operating Income | -$546.72M | -$466.07M | $17.55B | $215.64M | $68.56M |
| Net Income | -$99.92M | $113.87M | $8.47B | $110.37M | $44.93M |
| Net Margin | -22.3% | 7.6% | 43.7% | 21.6% | 18.3% |
| EPS | -$1.06 | $1.08 | $85.20 | $1.06 | $0.42 |
Rating Distribution
Strong Buy
0
0%
Buy
2
100%
Hold
0
0%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Morgan Stanley● Maintain
Overweight
2014-03-20Aegis Capital● Maintain
Buy
2013-11-13Aegis Capital● Maintain
Buy
2013-11-12Aegis Capital▲ Upgrade
Hold→Buy
2013-08-15Aegis Capital▲ Upgrade
Hold→Buy
2013-08-15Aegis Capital▲ Upgrade
Hold→Buy
2013-08-14Morgan Stanley▲ Upgrade
Underperform→Equal Weight
2013-05-15Morgan Stanley▲ Upgrade
Underperform→Equal Weight
2013-05-14Aegis Capital● Maintain
Hold
2013-03-14Aegis Capital● Maintain
Hold
2013-03-13Earnings History & Surprises
BEAT RATE
0%
Last 1 quarters
AVG SURPRISE
-50.0%
EPS vs Estimate
BEATS / MISSES
0/1
Last 1 quarters
LATEST EPS
$-0.08
Q3 '24
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q3 '24
No data
Q2 '24
No data
Q4 '23
No data
Q3 '23
No data
Q1 '23
-50.0%
$-0.03 vs $-0.02
Q3 '22
No data
Q1 '22
No data
Q4 '21
No data
Q2 '21
No data
Q2 '21
No data
Q4 '20
No data
Q3 '20
No data
No investor questions available.
Latest News
No news available